India to Jordan: Antitoxin Export Trade Route

To import Antitoxin formulations into Jordan, the following approvals and registrations are necessary:

1. Product Registration: All pharmaceutical products must be registered with the JFDA. This involves submitting a comprehensive dossier detailing the product's formulation, manufacturing process, safety, efficacy, and quality.

2. Importer Licensing: Importers must obtain an importer's card from the Ministry of Industry, Trade, and Supply. This card is essential for customs clearance purposes.

3. Import License: Certain pharmaceutical products may require an import license issued by the JFDA. Importers should verify if Antitoxin formulations fall under this category.

4. Good Manufacturing Practice (GMP) Compliance: The JFDA mandates that pharmaceutical products be manufactured in facilities compliant with GMP standards. Indian manufacturers exporting to Jordan must provide evidence of GMP certification.

Indian exporters of Antitoxin formulations must adhere to the following quality and GMP standards:

1. GMP Certification: Manufacturing facilities must possess valid GMP certificates recognized by the JFDA. This ensures that the products meet the required quality and safety standards.

2. Facility Inspections: The JFDA may conduct inspections of foreign manufacturing facilities to verify compliance with GMP standards. Indian exporters should be prepared for such inspections and maintain their facilities accordingly.

3. Regulatory Actions: As of March 2026, there have been no publicly reported regulatory actions by the JFDA against Indian pharmaceutical companies exporting to Jordan.

In the past 18 months, the following regulatory developments have impacted pharmaceutical imports into Jordan:

1. Import License Requirements: As of February 2026, the JFDA requires import licenses for specific pharmaceutical products. Importers should verify if Antitoxin formulations are affected by this regulation.

2. Importer Registration: In January 2024, the Ministry of Industry, Trade, and Supply mandated that all importers obtain an importer's card for customs clearance. This applies to all commercial goods, including pharmaceuticals.

Importers and exporters should stay informed about these regulations to ensure compliance and facilitate the smooth importation of Antitoxin formulations into Jordan.

As of 2025, Jordan's market for antitoxin formulations is characterized by a combination of domestic production and imports. The demand for these products is primarily driven by the prevalence of diseases requiring antitoxin treatments, the country's healthcare expenditure, and its commitment to universal health coverage. In 2024, Jordan's total imports of goods and services were valued at $26.9 billion, with pharmaceuticals being a significant component. While specific data on antitoxin imports is limited, the overall importation of pharmaceutical products indicates a reliance on external sources to meet healthcare needs. Domestic pharmaceutical manufacturing exists but may not fully satisfy the demand for specialized products like antitoxins, necessitating imports to bridge the gap.

Jordan applies a 0% MFN import duty rate on pharmaceutical products under HS code 30021220, which includes finished antitoxin formulations. This exemption aligns with Jordan's policy to facilitate access to essential medicines. Additionally, Jordan has established Free Trade Agreements (FTAs) with several countries, potentially offering preferential rates or exemptions for pharmaceutical imports. However, specific details regarding FTAs between India and Jordan affecting pharmaceutical tariffs are not readily available. Importers should consult the Jordan Customs Department for the most current information on applicable duties and any preferential trade agreements.

India is a notable supplier of antitoxin formulations to Jordan, with exports totaling $0.4 million USD across seven shipments from three manufacturers. This accounts for 3.2% of India's total antitoxin formulation exports, valued at $13.3 million. The primary Indian exporters to Jordan are VINS Bioproducts Limited and Modern Drug House. The main Jordanian importers include JIDSJ, CUST ID: JDS/AMN/001, and Al-Kawther Pharma Corp Police Faculty. While specific data on other countries supplying antitoxin formulations to Jordan is limited, major global suppliers typically include nations with robust pharmaceutical industries such as Germany, the United States, and Switzerland. India's competitive pricing and established pharmaceutical manufacturing capabilities position it favorably in the Jordanian market. However, without detailed import data, it is challenging to ascertain India's exact share of Jordan's total antitoxin imports or to compare pricing with competitors like China and European Union manufacturers.

India is a global leader in the pharmaceutical industry, supplying approximately 20% of the world's generic medicines by volume as of 2024. This extensive production capacity includes a wide range of finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections. The country's cost-effective manufacturing processes, driven by economies of scale and a skilled workforce, enable the production of high-quality antitoxin formulations at competitive prices. Additionally, India boasts a significant number of WHO-GMP and FDA-approved facilities, ensuring compliance with international quality standards for antitoxin formulations.

When comparing antitoxin formulation exports, India offers a compelling balance of cost and quality. Indian manufacturers provide finished dosage forms at prices lower than those from the European Union, where branded generics dominate. While China's generic formulations are competitively priced, India's stringent regulatory framework and adherence to international quality standards enhance its reputation for reliability. In Jordan, Indian antitoxin formulations are well-accepted, with a track record of consistent supply and compliance with local regulatory requirements.

The India-Jordan supply chain for antitoxin formulations has demonstrated reliability, supported by India's substantial manufacturing capacity and advanced packaging and cold chain logistics. Indian manufacturers maintain a strong regulatory compliance record, with numerous facilities holding WHO-GMP and FDA approvals. As of March 2026, there have been no significant supply disruptions reported in this trade route. Leading Indian manufacturers continue to invest in capacity expansion to meet growing global demand for antitoxin formulations.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of antitoxin formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): Discuss MOQs with suppliers to align with your procurement needs, as Indian manufacturers typically offer flexible terms to accommodate various buyer requirements.

• Establish Clear Payment Terms: Agree on payment terms that are standard in India-Jordan pharmaceutical trade, such as letters of credit or advance payments, to facilitate smooth transactions.

• Conduct Thorough Supplier Qualification: Perform comprehensive due diligence, including facility audits and quality assessments, to ensure suppliers meet international standards for antitoxin formulations.

• Stay Informed on Regulatory Compliance: Regularly monitor the regulatory status of selected suppliers to ensure ongoing compliance with both Indian and Jordanian pharmaceutical regulations.